- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03450863
Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device (GoBolus)
March 17, 2020 updated by: Novo Nordisk A/S
Impact of Fiasp® on Glycaemic Control in a Real World Population With Type 1 Diabetes Mellitus Using Flash Glucose Monitoring
The purpose of this study is to collect information about Fiasp® to evaluate how effective Fiasp® is in treating elevated blood sugar in patients with type 1 diabetes, compared with the participant's previous insulin treatment.
The study will also assess how satisfied the participants are with the treatment with Fiasp® and the impact of the treatment on quality of life.
The study has also been set up to learn more about how effective Fiasp® is in controlling the glucose levels during the day and night.
The duration of the study is expected to be approximately 2 years.
The participation is expected to be approximately 6-8 months for each patient.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
320
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Schweinfurt, Germany, 97421
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult patients with type 1 diabetes mellitus
Description
Inclusion Criteria:
- Signed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
- The decision to initiate treatment with commercially available Fiasp® has been made by the patient and the treating physician before and independently from the decision to include the patient in this study
- Male or female, age greater than or equal to 18 years at the time of signing informed consent
- Diagnosed with T1DM at least 1 year prior to inclusion in the study
- Stable treatment by MDI/CSII for at least 6 months prior to inclusion in the study. Stable treatment is defined as not changing the treatment method, with dose adjustments allowed
- Regular (defined as usage on a monthly basis) user of Freestyle Libre® flash glucose monitoring for at least 6 months as the only continuous glucose monitoring (CGM) system actively used and availability of a full 2 weeks sensor download as "csv" file with 80% completeness of the data (if more sensor data are available, the 2 week data closest to baseline visit will be used)
- Latest HbA1c value measured in the 3 months prior to inclusion in the study between 7.5-9.5%
Exclusion Criteria:
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Anti-diabetic treatment intensification during the last 3 months prior to inclusion in the study. Treatment intensification is defined as adding new anti-diabetic medication to previous treatment regimen
- Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods. Only highly effective methods of birth control are accepted (i.e. one that results in less than 1% per year failure rate when used consistently and correctly such as implants, injectables, combined oral contraceptives, certain intrauterine devices), or sexual abstinence or a vasectomised partner
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Fast-acting insulin aspart
Participants will receive fast-acting insulin aspart at the treating physician's discretion as part of the usual clinical practice.
The prescription and use of fast-acting insulin aspart is completely independent of this study.
Total study duration for the individual patient will be approximately 24 weeks.
|
Patients will be treated with commercially available fast-acting insulin aspart as bolus insulin (multiple daily injection [MDI]) or as insulin used in the insulin pumps (continuous subcutaneous insulin infusion [CSII]).
Dosing of fast-acting insulin aspart is individual and determined by the treating physician in accordance with the needs of the patient.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Glycated Haemoglobin (HbA1c)
Time Frame: Baseline (week 0), end of study (week 24 ± 4 weeks after baseline)
|
Measure in % point
|
Baseline (week 0), end of study (week 24 ± 4 weeks after baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Patient Reported Outcome: Impact of treatment measured by the overall score obtained from the Treatment Related Impact Measure For Diabetes (TRIM-D) questionnaire
Time Frame: Baseline (week 0), end of study (week 24 ± 4 weeks)
|
The TRIM-D Device is an eight item measure with two domains assessing Device Bother and Device Function.
This captures information on the ease of use, convenience, and handling of the device(s) used to take diabetes medication.
The measure has acceptable reliability, validity and ability to detect change.
|
Baseline (week 0), end of study (week 24 ± 4 weeks)
|
Change in Patient Reported Outcomes: Treatment satisfaction measured by the overall score obtained from the Diabetes Treatment Satisfaction Questionnaire (DTSQ)
Time Frame: Baseline (week 0), end of study (week 24 ± 4 weeks)
|
The DTSQs questionnaire will be used to assess subject's treatment satisfaction.
This instrument contains 8 items and measures the treatment for your diabetes (including insulin, tablets and/or diet) in terms of convenience, flexibility and general feelings regarding treatment.
|
Baseline (week 0), end of study (week 24 ± 4 weeks)
|
Change in fasting plasma glucose (FPG)
Time Frame: Baseline (week 0), week 12 (±4 weeks)
|
Measured in mmol/L
|
Baseline (week 0), week 12 (±4 weeks)
|
Change in fasting plasma glucose (FPG)
Time Frame: Baseline (week 0), end of study (week 24 ±4 weeks)
|
Measured in mmol/L
|
Baseline (week 0), end of study (week 24 ±4 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 22, 2018
Primary Completion (Actual)
September 4, 2019
Study Completion (Actual)
September 4, 2019
Study Registration Dates
First Submitted
February 23, 2018
First Submitted That Met QC Criteria
February 23, 2018
First Posted (Actual)
March 1, 2018
Study Record Updates
Last Update Posted (Actual)
March 18, 2020
Last Update Submitted That Met QC Criteria
March 17, 2020
Last Verified
March 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN1218-4412
- U1111-1204-0620 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
-
Peking Union Medical College HospitalUnknownType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus | Gestational Diabetes Mellitus | Pancreatogenic Diabetes Mellitus | Pregestational Diabetes Mellitus | Diabetes Patients in Perioperative PeriodChina
Clinical Trials on Fast-acting insulin aspart
-
Kirsten NørgaardUnknown
-
Stanford UniversityMedtronicCompletedDiabetes Mellitus, Type 1United States
-
Wake Forest University Health SciencesNational Institute on Aging (NIA); General ElectricCompletedMild Cognitive Impairment | Alzheimer's DiseaseUnited States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 1Austria
-
University of Ljubljana, Faculty of MedicineCompletedType 1 Diabetes MellitusSlovenia
-
Novo Nordisk A/SEnrolling by invitationDiabetes Mellitus, Type 1Belgium, France, Denmark, Sweden
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 1United States
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1United States, Germany
-
Novo Nordisk A/SCompleted
-
Novo Nordisk A/SCompletedDiabetes | Diabetes Mellitus, Type 1Germany, United States, India, Israel, Italy, Russian Federation, Japan, Finland, Serbia, Turkey, Bulgaria, Estonia, Czechia, Lithuania, Ukraine, Poland, Latvia, Puerto Rico